THE NATURAL HISTORY OF BLADDER CARCINOMA IN SITU AFTER INITIAL RESPONSE TO BACILLUS CALMETE-GÚERIN IMMUNOTHERAPY

2008 ◽  
Vol 179 (4S) ◽  
pp. 615-615 ◽  
Author(s):  
Ofer N Gofrit ◽  
Dov Pode ◽  
Galina Pizov ◽  
Kevin C Zorn ◽  
Ran Katz ◽  
...  
Lung Cancer ◽  
2005 ◽  
Vol 49 ◽  
pp. S183-S184
Author(s):  
Y. Miller ◽  
R. Keith ◽  
F. Hirsch ◽  
E. Dempsey ◽  
W. Franklin ◽  
...  

2020 ◽  
Vol 22 (1) ◽  
Author(s):  
Sarocha Chootipongchaivat ◽  
Nicolien T. van Ravesteyn ◽  
Xiaoxue Li ◽  
Hui Huang ◽  
Harald Weedon-Fekjær ◽  
...  

2005 ◽  
Vol 97 (2) ◽  
pp. 135-144 ◽  
Author(s):  
Bircan Erbas ◽  
Elena Provenzano ◽  
Jane Armes ◽  
Dorota Gertig

CHEST Journal ◽  
2005 ◽  
Vol 128 (3) ◽  
pp. 1736-1741 ◽  
Author(s):  
Arifa Pasic ◽  
Katrien Grünberg ◽  
Wolter J. Mooi ◽  
Marinus A. Paul ◽  
Pieter E. Postmus ◽  
...  

Author(s):  
Samantha L Heller ◽  
Anastasia Plaunova ◽  
Yiming Gao

Abstract Ductal carcinoma in situ (DCIS), breast cancer confined to the milk ducts, is a heterogeneous entity. The question of how and when a case of DCIS will extend beyond the ducts to become invasive breast cancer has implications for both patient prognosis and optimal treatment approaches. The natural history of DCIS has been explored through a variety of methods, from mouse models to biopsy specimen reviews to population-based screening data to modeling studies. This article will review the available evidence regarding progression pathways and will also summarize current trials designed to assess DCIS progression.


Sign in / Sign up

Export Citation Format

Share Document